<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2008-03-19" updated="2019-12-02">
  <drugbank-id primary="true">DB06293</drugbank-id>
  <name>Pegnivacogin</name>
  <description/>
  <cas-number>959716-28-0</cas-number>
  <unii>AYC3D1NPYB</unii>
  <average-mass>529.524</average-mass>
  <monoisotopic-mass>529.240046118</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.</indication>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Factor IXa, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Nucleic Acids, Nucleotides, and Nucleosides</category>
      <mesh-id>D009706</mesh-id>
    </category>
    <category>
      <category>Nucleotides</category>
      <mesh-id>D009711</mesh-id>
    </category>
    <category>
      <category>Oligonucleotides</category>
      <mesh-id>D009841</mesh-id>
    </category>
    <category>
      <category>Pegylated agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Polynucleotides</category>
      <mesh-id>D011119</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00019</drugbank-id>
      <name>Pegfilgrastim</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00061</drugbank-id>
      <name>Pegademase</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegademase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01839</drugbank-id>
      <name>Propylene glycol</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Propylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03394</drugbank-id>
      <name>Heptaethylene glycol</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegaptanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05202</drugbank-id>
      <name>Egaptivon pegol</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Egaptivon pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05321</drugbank-id>
      <name>PEG-uricase</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05860</drugbank-id>
      <name>Peginterferon alfacon-1</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Peginterferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06022</drugbank-id>
      <name>GlycoPEG-GCSF</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with GlycoPEG-GCSF.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06325</drugbank-id>
      <name>Pegpleranib</name>
      <description>The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06611</drugbank-id>
      <name>Pegsunercept</name>
      <description>The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06811</drugbank-id>
      <name>Polidocanol</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11661</drugbank-id>
      <name>Eptacog alfa pegol (activated)</name>
      <description>The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11707</drugbank-id>
      <name>Olaptesed Pegol</name>
      <description>The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12258</drugbank-id>
      <name>Abicipar Pegol</name>
      <description>The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12578</drugbank-id>
      <name>Lexaptepid Pegol</name>
      <description>The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12839</drugbank-id>
      <name>Pegvaliase</name>
      <description>The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12842</drugbank-id>
      <name>Pegamotecan</name>
      <description>The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14712</drugbank-id>
      <name>Elapegademase</name>
      <description>The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.13</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>8.54e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>({6-[2,6-bis({[(2-methoxyethoxy)carbonyl]amino})hexanamido]hexyl}oxy)phosphonic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>{6-[2,6-bis({[(2-methoxyethoxy)carbonyl]amino})hexanamido]hexyl}oxyphosphonic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>529.524</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>529.240046118</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H40N3O11P</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H40N3O11P/c1-30-13-15-32-19(25)22-11-7-5-9-17(23-20(26)33-16-14-31-2)18(24)21-10-6-3-4-8-12-34-35(27,28)29/h17H,3-16H2,1-2H3,(H,21,24)(H,22,25)(H,23,26)(H2,27,28,29)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>QGVYYLZOAMMKAH-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>190.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>124.63</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>55.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>52083501</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>